Protalix Biotherapeutics Inc. Revenue 2009–2025
Protalix Biotherapeutics Inc. annual/quarterly revenue history and growth rate from 2009 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Protalix Biotherapeutics Inc. revenue for the quarter ending March 31, 2026 was 33.8 M, a 233.73% increase year-over-year.
- Protalix Biotherapeutics Inc. revenue for the twelve months ending March 31, 2026 was 77.4 M, a 69.95% increase year-over-year.
- Protalix Biotherapeutics Inc. annual revenue for 2025 was 52.7 M, a 1.23% decrease from 2024.
- Protalix Biotherapeutics Inc. annual revenue for 2024 was 53.4 M, a 18.47% decrease from 2023.
- Protalix Biotherapeutics Inc. annual revenue for 2023 was 65.5 M, a 37.48% increase from 2022.
- Protalix Biotherapeutics Inc. annual revenue for 2022 was 47.6 M.
Protalix Biotherapeutics Inc. (PLX) — Frequently Asked Questions
Protalix Biotherapeutics Inc. (PLX) is a publicly traded US company. It has a market capitalization of $155M. In fiscal 2025 it reported revenue of $53M and net income of -$7M. Explore PLX's stock price, financial statements, earnings history, margins and key ratios below.
What is Protalix Biotherapeutics Inc.'s market cap?
Protalix Biotherapeutics Inc. (PLX) has a market capitalization of $155M.
What is the PLX stock price?
PLX trades at $1.97 (-0.51% on the day).
How much revenue does Protalix Biotherapeutics Inc. make?
Protalix Biotherapeutics Inc. reported revenue of $53M in fiscal 2025.
Is PLX profitable?
In fiscal 2025, Protalix Biotherapeutics Inc. reported net income of -$7M.